Jorge Quiroga Vila-rekin lankidetzan egindako argitalpenak (79)

2019

  1. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells

    Cell Death and Disease, Vol. 10, Núm. 1

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Insulin-like growth factor I (IGF-I) expressed from an AAV1 vector leads to a complete reversion of liver cirrhosis in rats

    PLoS ONE, Vol. 11, Núm. 9

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

2013

  1. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  2. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  3. Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure

    PLoS ONE, Vol. 8, Núm. 1

2011

  1. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages

    Annals of Surgical Oncology, Vol. 18, Núm. 7, pp. 1964-1971

2010

  1. A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

    Cancer Gene Therapy, Vol. 17, Núm. 12, pp. 837-843

  2. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 77, Núm. 5, pp. 1441-1448

2009

  1. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma

    Hepato-Gastroenterology, Vol. 56, Núm. 96, pp. 1683-1688

  2. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report

    Clinical Transplantation, Vol. 23, Núm. 4, pp. 532-536

2008

  1. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria

    Liver Transplantation, Vol. 14, Núm. 3, pp. 272-278

2006

  1. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 66, Núm. 3, pp. 792-800

2005

  1. De novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival

    Liver Transplantation, Vol. 11, Núm. 1, pp. 89-97

  2. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial

    Journal of Hepatology, Vol. 43, Núm. 4, pp. 630-636

  3. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas

    Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010

  4. Nonmelanoma skin cancer after liver transplantation. Study of risk factors

    Liver Transplantation, Vol. 11, Núm. 9, pp. 1100-1106

  5. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis

    American Journal of Gastroenterology, Vol. 100, Núm. 6, pp. 1311-1316